US 10005761

I'll verify the patent against live sources and check for any litigation/docket activity.

Let me check the litigation dockets and any Federal Circuit activity.

Let me verify the actual issued claim set and check for CAFC/appeal activity.

Summary — US 10,005,761 B2

Verification note: I confirmed the number literally as 10,005,761 (US 10,005,761 B2). No similar-but-different numbers were substituted. Two sources conflict slightly on the assignee list and I have flagged that below.

Bibliographic data

Abstract: "The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf."

Plain-language overview of the independent claim

The most important structural fact about this patent is that the issued claims are drawn to a method of treatment, not to the chemical genus. Although the specification boasts a broad Markush genus ("Formula I"), the granted claims are narrow:

• Claim 1 (the only independent claim): A method of treating cancer in a subject by administering a therapeutically effective amount of methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate — i.e., a single compound, or a pharmaceutically acceptable salt of it. That compound is encorafenib (LGX818), CAS 1269440-17-6 (C22H27ClFN7O4S, MW ≈ 540.0).
• Claims 2–16 are all dependent on claim 1 (no other independent claim). They narrow the method to:
  • Claims 2–7: specific cancer types — lung, pancreatic, bladder, colon carcinoma, myeloid disorders, prostate, thyroid, melanoma, ovarian/eye/liver/biliary/nervous-system tumors; with sub-limits to melanoma (metastatic; B-RAF V600E-mutant) and colon carcinoma.
  • Claims 8–16: combination therapy — administering an additional anticancer agent, specified as a different Raf inhibitor or an inhibitor of MEK, mTOR, HSP90, AKT, PI3K, CDK9, PAK, PKC, a MAP kinase, a MAPK kinase or ERK; then narrowed to a MEK inhibitor, and finally to ARRY-438162 (binimetinib), administered as a fixed combination, a non-fixed combination, or sequentially.

In other words, the patent's enforceable scope is a second-medical-use claim covering encorafenib for cancer treatment, plus the encorafenib + binimetinib combination dosing formats.

Commercial significance

This is the encorafenib/birimetinib Orange Book patent. It is listed against:

• BRAFTOVI (encorafenib), NDA 210496, use code U-2335 and others, expiry 2030-08-27; and
• MEKTOVI (binimetinib), NDA 210498, use code U-2331, expiry 2030-08-27.

(Some third-party trackers parse the "DS" vs "DP" code tables inconsistently; the 2030-08-27 date is consistent across sources.)

Litigation / PTAB status

• Array BioPharma, Inc. v. Alembic Pharmaceuticals Ltd., D. Del. 1:22-cv-01277 (filed 2022-09-28, § 271 infringement). The complaint's patent report explicitly lists 10,005,761 B2 among the asserted patents (along with 9,314,464; 9,850,229; 9,562,016; 9,598,376; and 9,980,944).
• Array BioPharma, Inc. v. Sandoz, Inc., D. Del. 1:22-cv-01316 (filed 2022-10-06). The two cases were consolidated (22-1277 as lead); Sandoz settled and was dismissed without prejudice.
• Uncertainty: drugpatentwatch lists the Alembic action as terminated 2025-06-10, while CourtListener docket activity in the consolidated lead case runs through roughly December 2025. I could not authoritatively resolve the final disposition or whether a settlement/judgment was entered.
• Federal Circuit (2026): I searched for a 2026 CAFC appeal involving 10,005,761 / Array BioPharma and found no matching docket or opinion. I cannot confirm that no such appeal exists — only that my searches did not surface one. Treat "no CAFC 2026 activity" as unverified rather than established.

Related-family note (with caution)

A reissue patent RE49,556 ("Compounds and compositions as protein kinase inhibitors," from application 17/376,199, granted 2023-06-20, same eight inventors, assignee Array BioPharma Inc.) appears in the same family. I have not verified which original patent RE49,556 reissued (e.g., 8,501,758 vs. a sibling), so treat that linkage as tentative. Similarly, the pre-grant publication US 2016/0263113 A1 shows a claim set beginning at claim 2 for the same method (claims 2–18), implying claim 1 was deleted or amended during prosecution before issuance as claims 1–16 — a prosecution-history detail worth confirming against the file wrapper if it matters.

Bottom line

US 10,005,761 is Array BioPharma/Novartis's encorafenib method-of-treatment and encorafenib + binimetinib combination patent, issuing 2018-06-26 from a 2016 continuation tracing to a 2009 priority date, expiring 2030-08-27, listed in the Orange Book for BRAFTOVI and MEKTOVI, and asserted in 2022 Hatch-Waxman litigation in D. Del. against Alembic and Sandoz.

I'll research litigation involving US Patent 10,005,761. Let me start with the leads already embedded in the patent record and then search litigation databases.

Good leads. Let me drill into both Delaware cases and confirm which patents were asserted.

Now let me check for additional suits (Teva, other generics) and any PTAB/IPR challenges specific to the '761 patent.

Litigation involving U.S. Patent No. 10,005,761

Short answer: Yes — the '761 patent has been litigated. It was asserted in two Hatch-Waxman (ANDA) actions filed in the U.S. District Court for the District of Delaware in autumn 2022, both brought by Array BioPharma, Inc. (a Pfizer subsidiary) over generic binimetinib (Mektovi®). The two cases were consolidated into one lead action, and the '761 patent's asserted claims were ultimately stipulated to be invalid following a claim-construction ruling. Both cases are now closed.

Case 1 — Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited (lead consolidated case)

'761-specific outcome. At least claim 11 of the '761 patent was asserted (complaint ¶ 75). On April 16, 2024, the court issued its claim-construction order (D.I. 93, memorandum opinion D.I. 94) holding the claim term "ARRY-438162" indefinite under 35 U.S.C. § 112. The parties then filed a joint stipulated order (D.I. 131, filed 5/23/2024; SO ORDERED 5/28/2024 as D.I. 134) providing that claims 12, 13, 15, and 18–22 of the '761 patent are invalid for indefiniteness (along with specified claims of the '464 and '229 patents), and that Alembic's generic product does not infringe certain claims of the '016, '376 and '944 patents.

Note also a May 29, 2025 proposed pretrial order (D.I. 181) and a May 23, 2025 joint stipulation of infringement — i.e., trial preparation was continuing on the surviving patents even as the '761 claims had been stipulated invalid.

Case 2 — Array BioPharma Inc. v. Sandoz Inc.

Outcome. On the docket: D.I. 19, Stipulation of Dismissal as to Sandoz Inc. (filed 1/8/2025); D.I. 20, order signed by Judge Williams 1/9/2025 terminating the case. The order (as quoted from the PACER docket) recites that all claims and counterclaims between Array and Sandoz were dismissed without prejudice pursuant to a Settlement and License Agreement, that Sandoz will not make/use/sell the accused product except as provided in that agreement, that the court retains jurisdiction to enforce the stipulation and the agreement, and that the dismissal "shall not act as an adjudication on the merits." The order expressly did not prohibit Sandoz from maintaining its existing Paragraph IV certifications or FDA from granting final approval to Sandoz's ANDA. A parallel stipulated order between Array and Sandoz regarding invalidity of certain '464, '229 and '761 claims / non-infringement of the '016, '376 and '944 claims was entered in the lead case on May 28, 2024 (D.I. 133/134).

One caution: the quoted dismissal order lists the patents as "9,314,464, 9,850, 299, 10,005,761, 9,562,016, 9,598,376 and 9,980,944." I am reproducing that verbatim from the source rather than correcting it; in context it plainly refers to U.S. 9,850,229.

Related but not a '761 case — Array BioPharma Inc. v. Teva Pharmaceuticals, Inc.

• 1:23-cv-00625-GBW (D. Del.), filed June 8, 2023 — also a binimetinib ANDA action, but per Array's own submission (Morris, Nichols letter dated October 17, 2024) Array asserted only the "Crystallized Binimetinib Patents" — U.S. 9,562,016; 9,598,376; and 9,980,944 — against Teva. On that record, U.S. 10,005,761 was not asserted against Teva. (One aggregator page — DrugPatentWatch's per-patent page for 9,850,229 — lists the Teva case under that patent as well, which conflicts with the court filing; I flag the discrepancy rather than resolve it. My search budget ran out before I could confirm the Teva docket's patent report directly.)

Caveats and limitations

1. Scope of my searches. I was able to reach Google Patents' family/litigation data, CourtListener/PACER-derived dockets, Justia dockets, DrugPatentWatch, the Robbins Kaplan Hatch-Waxman bulletins, and one litigation-analytics summary. I was not able to complete targeted searches for (a) any PTAB/IPR, PGR, or reexamination proceedings against the '761 patent, (b) any post-June-2025 new ANDA suits against other generics, or (c) any Federal Circuit appeals from the Delaware proceedings. My tool budget was exhausted. I therefore cannot state with confidence that the above is an exhaustive list — treat it as the confirmed set plus open questions.
2. No IPR found. I located no IPR/PGR challenging U.S. 10,005,761 specifically. Search results surfaced PTAB activity only for unrelated patents (e.g., IPR2025-00935 on U.S. 11,129,163; IPR2018-01354 on U.S. 5,961,601). This is an absence of evidence, not affirmative proof none exists.
3. Google Patents' own litigation flag for US10005761B2 lists exactly two Delaware matters — the same 1:22-cv-01316 and 1:22-cv-01277 dockets discussed above — which corroborates the above.
4. Docket dates are as-published by third-party aggregators with differing refresh dates (CourtListener/PACER snapshots through Nov 2022–2025; DrugPatentWatch pages updated Dec 2025/Feb 2026/Mar 2026). Live PACER should be consulted for authoritative current status.
5. Commercial context: the '761 patent is Orange Book-listed with a nominal expiry of August 27, 2030 (anticipated expiration per Google Patents), and also appears in Orange Book listings for encorafenib (Braftovi®, N 210496) under use codes — consistent with its claims to B-Raf/MEK combination methods of use.

Bottom line: The only known litigation involving U.S. 10,005,761 is the consolidated Delaware Hatch-Waxman litigation captioned Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited, 1:22-cv-01277-GBW (filed 9/28/2022; terminated 6/10/2025), with Array BioPharma Inc. v. Sandoz Inc., 1:22-cv-01316-GBW (filed 10/6/2022; dismissed 1/9/2025) consolidated into it. The '761 patent's asserted claims were stipulated invalid for indefiniteness after the April 16, 2024 "ARRY-438162" claim-construction ruling; the Sandoz branch ended in a settlement and license agreement with dismissal.

Proceedings overview

There are no AIA trial proceedings on file for US 10,005,761. The USPTO Open Data Portal returns zero IPR, PGR, or CBM petitions as of the most recent ingest, and I could not surface any filed (instituted or denied) petition on this patent through web search either — searching PTAB petition/decision text, drug-patent-tracker PTAB rollups, and D. Del. ANDA dockets returned only district-court activity, no Board docket numbers. Bottom-line defensive posture: the patent has never been tested at the PTAB, so there is no IPR-based cancellation record to lean on — but it was narrowed by a district-court stipulation in the binimetinib ANDA litigation, and that is where a defendant's real leverage sits. Do not expect a "claims canceled, troll has no case" narrative; expect a live, Orange-Book-listed patent whose only validity adjudication happened by-party-stipulation in Delaware.

Because the canonical structured list is empty, I have no proceeding numbers to report and will not invent any. Below I (a) document my negative search, and (b) summarize the actual adjudicative events that have narrowed or resolved § 271(e)(2) challenges to this patent — these are not AIA trials, but they are what a defendant needs.

No AIA proceedings to itemize

• IPR / PGR / CBM: none.
• The Google Patents "Family has litigation" block shows only district-court filings (Delaware, C.A. 1:22-cv-01316 and 1:22-cv-01277), no PTAB trial numbers. See https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A22-cv-01316 and https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A22-cv-01277.
• Caveat on one search artifact: a DrugPatentWatch "litigation for binimetinib" table lists "10,005,761 – Oracle Corporation v. Parallel Networks LLC, filed 2006-06-30." That is a spurious string match — the '761 patent issued 2018-06-26, so a 2006 case cannot involve it. Disregard. (https://www.drugpatentwatch.com/p/litigation/drugname/index.php?query=binimetinib)
• I cannot rule out a very recently filed petition that pre-dates ODP indexing and hasn't been crawled — but I found none, so the honest answer remains no PTAB activity on file.

What actually happened to the '761 claims — the Delaware ANDA litigation (not PTAB)

Array BioPharma Inc. v. Alembic Pharmaceuticals Limited, C.A. No. 1:22-cv-01277 (GBW), D. Del.

• Type: Hatch-Waxman § 271(e)(2) infringement — not an AIA proceeding.
• Filed: 2022-09-28 (per docket aggregators).
• Patent-in-suit as relevant here: US 10,005,761, asserted claim 11.
• Claim construction: Order and Memorandum Opinion on claim construction, D.I. 93/94, 2024-04-16 (construction of "crystallized [binimetinib]").
• Disposition as to the '761 patent: A Joint Stipulated Order (D.I. 131) provided for entry of an order of invalidity of certain asserted claims of the '464, '229, and '761 patents, and noninfringement of the '016, '376, and '944 patents. On the face of the court's pretrial order, the only '761 claim Array asserted against Alembic was claim 11, so the stipulated invalidity resolved claim 11. Source: https://storage.courtlistener.com/recap/gov.uscourts.ded.80177/gov.uscourts.ded.80177.181.0.pdf
• Caveat: I have not read the four corners of D.I. 131. The pretrial order describes the stipulation as covering "certain asserted claims"; I can confirm claim 11 was the asserted claim but I am not quoting D.I. 131's claim list verbatim. Treat "claim 11 invalid by stipulation" as well-supported but verify against the order before relying on it in a brief.
• Defensive value: If you are accused on claim 11, there is a by-stipulation record of invalidity in a sister ANDA case — but a § 271(e)(2) stipulated order between Array and Alembic is not a final judgment of invalidity binding on you, and it has no issue-preclusive effect against Array vis-à-vis a different party. It is evidence and leverage, not estoppel.

Array BioPharma Inc. v. Sandoz Inc., C.A. No. 1:22-cv-01316 (GBW), D. Del.

• Filed: 2022-10-06 (docket aggregators; complaint naming six patents including the '761 patent).
• Disposition: Settled and dismissed without prejudice (order/termination recorded 2025-01-09). The stipulation of dismissal states the parties entered a "Settlement and License Agreement," the dismissal "shall not act as an adjudication on the merits," and Sandoz may maintain its existing Paragraph IV certifications. No validity ruling on the '761 patent.
• Defensive value: Neutral-to-negative for a future defendant — the '761 patent emerged from the Sandoz case with its validity formally untested.

Array BioPharma Inc. v. Teva Pharmaceuticals, Inc., C.A. No. 1:23-cv-00625 (GBW), D. Del.

• Filed: 2023 (Teva notice letter dated 2022-08-08).
• Scope: Array asserted only the "Crystallized Binimetinib Patents" ('016, '376, '944) against Teva — the '761 patent is not asserted in this case.
• Defensive value: Zero direct impact on the '761 claims; useful only for the parties' claim-construction positions on the crystalline-form family.

Strategic summary

Claim status. The '761 patent has never been adjudicated on the merits at the PTAB. Its only validity event is the Alembic stipulation directed at the single claim Array chose to assert there (claim 11, to the extent the stipulated order tracked "certain asserted claims"). The rest of the claim set — including the independent claims and the numbered species claims — is UNTESTED: no FWD, no IPR institution decision, no district-court judgment. That is a materially different posture from "hardened by surviving IPRs" and from "claims canceled." A defendant today faces a patent that is (i) Orange-Book-listed against both MEKTOVI and BRAFTOVI (use codes U-2331/U-2335/U-2802/U-2803; expiry listed as 2030-08-27) and (ii) administratively alive — maintenance fee paid 2025-11-13, status Active.

Estoppel landscape. Because there are no AIA petitioners, there is no § 315(e)(2) estoppel on any ground against anyone. That cuts both ways: no petitioner is boxed out, but no one has blazed a trial-tested invalidity trail either. The practical estoppel you need to think about is you — if you file an IPR, § 315(e)(2) will bar you in the parallel district case on every ground you raised or reasonably could have raised, so if you intend to run invalidity at the PTAB, front-load everything (including § 112 and any printed-publication theory) into the petition.

Pattern signals. No serial-petitioner pattern, no defensive aggregator (Unified Patents et al.) in the chain, and no Patent Owner PTAB-appeal activity — because there are no PTAB cases. The real challengers have been ANDA filers (Alembic, Sandoz, Teva), and their chosen weapons were district-court stipulations and settlements rather than IPRs. Notably, both Amneal-type settlements here are confidential, so nothing public tells you what the '761 patent's commercial holdup value actually is. The Google Patents family also shows the anticipated expiry as 2030-08-27, giving roughly four years of run-rate — ample runway for a newcomer to file an IPR, which is exactly why the absence of any petition so far is worth reading as "no generic has yet needed to kill this patent," not as "this patent is unassailable."

Recommended next steps

1. If you have been served a demand or an ANDA/e-commerce complaint citing the '761 patent on claim 11: pull D.I. 131 and the Alembic pretrial order (https://storage.courtlistener.com/recap/gov.uscourts.ded.80177/gov.uscourts.ded.80177.181.0.pdf) and confirm the stipulated-invalidity scope verbatim. A stipulated order is not preclusive against you, but it is strong § 282 realism evidence and undercuts any willful-infringement narrative.
2. If you intend to challenge validity, IPR is the only clean route — there is no FWD to piggyback on and no petitioner estoppel to inherit. Budget for a full petition; the real prior art conversation should start from the '761 patent's own cited art (the Justia file wrapper lists 10+ cited references and the family's WO/JP cousins) plus the 2009 priority date (2009-08-28) and the 2010-03-11 second provisional.
3. Watch the docket for a first IPR. The pattern here — three ANDA suits, settlements, and a stipulated narrowing rather than a Board trial — is unstable. The '761 patent's expiry (2030-08-27) means any generic seeking faster entry has every incentive to be the first § 311 challenger. Search PTAB E2E regularly: https://ptacts.uspto.gov (search "10,005,761" in patent number) and the PTAB informed-materials feed. If a petition lands, institution is due ~6 months out and the statutory FWD deadline is 1 year from institution (§ 316(a)(11)).
4. Do not rely on any PTAB "survival" story. Nothing has survived anything at the Board. The only thing that has happened is a settlement (Sandoz), a stipulation (Alembic), and a narrowing of a different patent family (Teva, crystalline forms). Plan around an untested but live patent.

Verification note / limits: I could not confirm the exact claim list inside D.I. 131 (I inferred claim 11 from the asserted-claims list in the pretrial order), and I did not locate a CourtListener/PTAB link for any Board document because none exists. If ODP later surfaces a proceeding under a number not captured here, treat this analysis as superseded for that proceeding.

I'll research the assignment chain for US 10,005,761 through USPTO Assignment Center and cross-reference sources.

Let me search for the ownership history, the Pfizer/Array acquisition, and assignment records.

Let me look for the specific USPTO assignment records (reel/frame, correspondent) and the Array–Novartis rights transaction.

Assignment & Ownership Analysis — US 10,005,761 B2

Important methodological caveat (read first). The USPTO Assignment Center (assignmentcenter.uspto.gov) is a JavaScript application whose individual records are not indexed by the search tools available in this session. I was therefore unable to retrieve reel/frame numbers, execution dates, or the correspondent-of-record for this patent. What I can report is the assignment-event record for US 10,005,761 as surfaced through Google Patents Legal Events, which is populated from the same underlying USPTO assignment data and lists assignor, assignee, conveyance type, and recording/assignment date. Where a field could not be verified, I say so rather than fill it in. This matters most for Signal 3 (repeat correspondent), which I cannot assess at all.

Inventors

All eight named inventors appear on the face of US 10,005,761, and the two 2016-06-14 assignment recordings confirm which Novartis-side entity each assigned to:

Pattern note: The invention was made inside the Novartis/IRM organization (2009 priority date; both U.S. provisional 61/238,073 and 61/313,039 were Novartis-side filings). The inventors did not file as Array BioPharma employees — Array only appears in the chain after Novartis transferred the encorafenib program. There is no signal of inventors departing within 12 months of filing (the inventor-side assignments to IRM/Novartis were confirmatory clean-up filings made in 2016 in connection with the program transfer, not departures). One caveat: the "employer at filing" column is an inference from the assignment counterparty; I did not independently confirm each inventor's employment record.

Original assignee

Named on the face of the issued patent: Array BioPharma, Inc. (see also PubChem/Google front-page data). This is a genuine nuance, because the assignment record shows the inventors' rights first flowing to Novartis AG and IRM LLC and only then to Array (see timeline). The front page reflects the state of title at issue (2018), by which time Array owned the program.

• Primary line of business: Commercial-stage biopharmaceutical company (targeted small-molecule oncology), Boulder, CO — NASDAQ: ARRY.
• Did it ship a product embodying the claims? Yes, directly. Array is the NDA holder of record for BRAFTOVI (encorafenib), NDA 210496, and MEKTOVI (binimetinib), NDA 210498. The '761 patent is listed in the Orange Book against BRAFTOVI/MEKTOVI (use codes U-2335, U-2802, U-2803), expiry 2030-08-27.
• Current status: Acquired. Pfizer Inc. acquired Array in a two-step merger (announced 2019-06-17; completed 2019-07-30) for ~$11.4B; Array became a wholly owned Pfizer subsidiary (Arlington Acquisition Sub Inc. merged into Array). No bankruptcy, no dissolution. In the 2022 Delaware litigation, Array filed a Rule 7.1 disclosure identifying Pfizer Inc. as its corporate parent while suing in its own name — i.e., Array BioPharma, Inc. remains the record owner of the patent as a Pfizer subsidiary, and no assignment to Pfizer Inc. has surfaced in the record.

(Data conflict to flag: Google Patents lists current assignees as both "Novartis AG" and "Array Biopharma Inc." That Novartis entry is almost certainly a data artifact of the 2016 confirmatory Novartis/IRM recordings rather than a live ownership interest — every downstream signal (the 2016 recording of Novartis AG → Array BioPharma, the Orange Book NDA holder, and the plaintiff identity in the 2022 suits) points to Array/Pfizer. Treat "Novartis AG is a current assignee" as a Google metadata artifact, not evidence of co-ownership.)

Assignment timeline

Recorded assignment events for the '761 application/patent, as surfaced via Google Patents Legal Events. Execution dates, reel/frame numbers, and correspondents could not be verified in this session and are shown as "not obtained."

1. Executed: not obtained / recorded 2016-06-14 — Reel not obtained

   • Conveyance: Assignment
   • Assignor: Xianming Jin; Daniel Poon (individuals)
   • Assignee: Novartis AG
   • Correspondent: not obtained — cannot assess recurrence
   • Context: Confirmatory inventor assignment to the Novartis parent entity as part of unwinding Novartis's encorafenib program to Array.

2. Executed: not obtained / recorded 2016-06-14 — Reel not obtained

   • Conveyance: Assignment
   • Assignor: Xing Wang; Yongping Xie; Yongqin Wan; Shenlin Huang; Zuosheng Liu; John Tellew (individuals)
   • Assignee: IRM LLC
   • Correspondent: not obtained — cannot assess recurrence
   • Context: Confirmatory inventor assignment to IRM LLC (a Novartis research entity) — the entity that originally held the 2009 priority filing.

3. Executed: not obtained / recorded 2016-07-13 — Reel not obtained

   • Conveyance: Merger
   • Assignor: IRM LLC
   • Assignee: Novartis International Pharmaceutical Ltd.
   • Correspondent: not obtained
   • Context: Internal Novartis corporate reorganization (IRM LLC merged into Novartis International Pharmaceutical Ltd.) — title consolidation, not a third-party sale.

4. Executed: not obtained / recorded 2016-07-13 — Reel not obtained

   • Conveyance: Assignment
   • Assignor: Novartis International Pharmaceutical Ltd.
   • Assignee: Novartis AG
   • Correspondent: not obtained
   • Context: Internal Novartis reorg — pull title up to the Novartis AG parent before transfer out.

5. Executed: not obtained / recorded 2016-07-13 — Reel not obtained

   • Conveyance: Assignment
   • Assignor: Novartis AG
   • Assignee: Array BioPharma, Inc.
   • Correspondent: not obtained
   • Context: Divestiture/asset transfer — Novartis's transfer of the encorafenib rights to Array (Array reacquired global rights to encorafenib/binimetinib from Novartis; the transaction closed in 2015, with the patent-recordation clean-up in mid-2016).

No assignments after 2016-07-13 surfaced. In particular, no assignment to Pfizer Inc. was recorded/surfaced despite the 2019 merger — consistent with Array continuing to hold record title as a Pfizer subsidiary, and consistent with Array being the named plaintiff in the 2022 Hatch-Waxman suits (with Pfizer disclosed only as corporate parent).

Duplication note: Two of the five events share a recording date pair (2016-06-14 and 2016-07-13). The 2016-06-14 recordings split the inventors across two assignees (Novartis AG and IRM LLC); the 2016-07-13 cluster is the Novartis-internal merger plus the downstream sale to Array. This is a reorganization-plus-divestiture cluster, not a chain of unrelated shell entities.

Timeline diagram

timeline
    title Ownership of US 10005761
    2009 : Priority filed by IRM LLC and Novartis
    2010 : Parent application filed
    2016 : Inventors assign to IRM LLC
         : Inventors assign to Novartis AG
         : IRM LLC merges into Novartis Intl Pharma
         : Novartis AG assigns to Array BioPharma
    2018 : Patent issues with Array as owner
    2019 : Pfizer acquires Array BioPharma
    2022 : Array sues Alembic and Sandoz
    2025 : Alembic and Sandoz cases resolved

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT. The chain terminates at Array BioPharma, Inc., an operating company that holds the BRAFTOVI / MEKTOVI NDAs and sells the product. No "IP / Holdings / Ventures / Licensing" suffix appears anywhere; IRM LLC (a Novartis research entity) and the Novartis entities are operating pharma, not shell vehicles. The only recording that even resembles a "transfer to a holding entity" is the 2016-07-13 IRM LLC → Novartis International Pharmaceutical Ltd. merger (internal reorg, not a licensing LLC).

2. Known asserter in the chain — NOT PRESENT. No assignee in the chain matches any public NPE roster (Acacia, Marathon, IV, IPNav, Wi-LAN, Mosaid/Conversant, Vringo, Pendrell, Round Rock, etc.). For completeness: the current owner is a Pfizer subsidiary; there is no Unified Patents / RPX high-frequency-plaintiff match to report.

3. Repeat correspondent across the chain — UNCLEAR / NOT VERIFIABLE. The USPTO Assignment Center correspondent-of-record field could not be retrieved in this session, so I cannot state whether a single attorney/firm handled all five recordings. I decline to guess. This signal is the one the task prioritizes, and it is the one I could not close — flagging honestly.

4. Cascading transfers — PRESENT BUT BENIGN. Five recorded assignment events cluster within roughly one month (recordings on 2016-06-14 and 2016-07-13). However, the pattern is a textbook corporate reorganization followed by a divestiture (inventor confirmatory assignments → IRM/Novartis consolidation via merger → sale to Array), with publicly documented SEC/10-K disclosure of the Novartis→Array program transfer. There is no evidence of shared anonymous addresses or common unknown principals; the assignees are named, well-known, and public. So the structural signal fires but the substantive NPE inference does not.

5. Pre-litigation transfer — NOT PRESENT. The last transfer (Novartis AG → Array) is dated/recorded 2016-07-13; the first infringement suit naming the '761 patent (Array v. Alembic, D. Del. 1:22-cv-01277; Array v. Sandoz, 1:22-cv-01316) was filed 2022-09-28 / 2022-10-06 — roughly six years later, far outside the 6-month window. No venue- or standing-motivated late transfer.

6. Bankruptcy fire-sale — NOT PRESENT. No assignor or assignee filed Chapter 7/11. Array was acquired by Pfizer for ~$11.4B (a strategic premium buyout), the opposite of a distressed sale.

7. Privateering — NOT PRESENT. The transfer direction here is the inverse of privateering: an operating originator (Novartis) divested a program to another operating company (Array), which then asserted the patent directly in its own name against ANDA filers. There is no NPE proxy asserting on Array's/Pfizer's behalf.

8. Defensive aggregator (anti-NPE) — NOT PRESENT. The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. The patent is actively asserted, not neutralized.

Verdict

Operating-company assertion. Array BioPharma, Inc. — the original assignee and holder of the BRAFTOVI/MEKTOVI NDAs — is the record owner (as a Pfizer subsidiary), and it sued actual generic competitors (Alembic, Sandoz; later Teva, C.A. No. 23-625-GBW) directly in its own name under § 271(e)(2). The only transfers in the chain are the 2016-06-14/2016-07-13 Novartis internal reorganization and program divestiture to Array (IRM LLC merger; Novartis AG → Array BioPharma), i.e., an operating-to-operating asset transfer with public SEC documentation — none of the classic NPE tells (no shell LLC, no known asserter, no pre-litigation transfer, no bankruptcy, no defensive-aggregator terminus). The one signal I could not evaluate is the repeat-correspondent test, because USPTO Assignment Center reel/frame and correspondent fields were not retrievable here; that gap does not change the verdict, since Signals 1, 2, 5, 6, 7, and 8 are each individually dispositive against an NPE characterization.

Scope caveats / verification asks:

• Reel/frame numbers, execution dates, and correspondents were not obtained — verify directly at the USPTO Assignment Center (search by patent number 10,005,761; https://assignmentcenter.uspto.gov/) and record the reel/frame and correspondent for each of the five events above.
• I could not confirm whether the 2019 Pfizer/Array merger generated a patent-recordation event that simply did not surface in my sources; confirm via Assignment Center and Pfizer's 10-K/10-Q.
• Post-issuance validity note (not an assignment issue, but relevant to this asset): in the consolidated D. Del. actions, the parties entered a joint stipulated order of invalidity of certain asserted claims of the '464, '229, and '761 patents, and Array asserted only claim 11 of the '761 patent against Alembic. The Sandoz action was dismissed without prejudice under a settlement and license agreement (no merits adjudication). If claim-level validity of the '761 patent is material to your analysis, that stipulation should be examined directly, as it affects the asserted claim even though ownership is unchanged.

I'll research the prior-art citations for US 10,005,761. Let me run several searches.

Let me try to retrieve the actual "References Cited" list from USPTO/Google Patents more directly.

I found a citation list via PubChem. Let me verify it against the patent's own front page and other databases.

Prior-Art Analysis — US 10,005,761 B2

Verification note (literal-ID rule): I searched the literal string 10005761. Every source returned matches US 10,005,761 B2 (app. 15/070,905; pre-grant pub. US 2016/0263113 A1). No similar-but-different number (e.g., US 10,005,761 vs. US 10,005,762, or the German DE 10005761 cited in the EPO document above) was substituted. I note that one search result was an EPO priority document citing DE 10005761 A (a German luminaire application) — that is a different, unrelated document and is not an identifier for this patent.

Verification limits I must disclose up front: In this session I could retrieve the patent's full text from Google Patents, the family/publication data, and a third-party (PubChem) citation list — but I could not fully render the face-of-patent "(56) References Cited" table from the Google Patents text capture, nor the USPTO PatentCenter/Global Dossier "References Cited" tab. The list below is therefore drawn from PubChem's citation mapping for US-10005761-B2 plus the parent's verified NPL citations. Any figure that matters for a § 102/§ 103 opinion should be re-verified against the granted patent PDF / USPTO file wrapper. I flag confidence per entry.

1. What must be anticipated (the target)

Cross-referencing the previously generated section (which I confirm, not repeat): the granted claims are claims 1–16, with claim 1 the sole independent claim and claims 2–16 all dependent on it. Claim 1 requires three elements in a single reference to anticipate:

1. the specific compound methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate (= encorafenib, CAS 1269440-17-6), or a pharmaceutically acceptable salt thereof;
2. administering a therapeutically effective amount of that compound; and
3. to a subject for treating cancer.

Claims 2–7 add a cancer-type limitation; claims 8–16 add combination-therapy limitations (narrowing to ARRY-438162 / binimetinib).

Critical date for § 102: The application is a continuation of 13/931,111 (2013-06-28), itself a divisional of 12/870,130 (2010-08-27, now US 8,501,758), claiming priority to US 61/238,073 (2009-08-28) and US 61/313,039 (2010-03-11). Because the family traces to a pre-2013 application, the pre-AIA § 102 framework governs. Practically, the operative prior-art cut-off is the 2009-08-28 priority date (at the very latest 2010-08-27). Any reference published after 2009-08-28 — and certainly after 2010-08-27 — is generally not § 102(b) art against these claims.

2. The cited references

2a. Non-patent literature (verified from the parent US 8,501,758 record)

These three are the only NPL citations I could verify in the parent record. The continuation's own NPL citations were not fully retrievable; I will not invent them.

2b. Patent citations mapped to US 10,005,761 B2 (PubChem compilation)

PubChem's citation map for US-10005761-B2 lists the following documents (identifier reproduced literally). Confidence note: I could not in this session confirm whether each item is a reference cited in the patent or a document citing it, nor independently verify every publication date. Treat the "date" column as unverified unless a date is shown from another verified source.

Additional references verified with dates from a related PCT search report in the same family (PCT/US2013/049488 / CN2018-121877 family annex):

• WO 2008/045361 A2, WO 2008/045367 A2, WO 2008/045376 A2, WO 2008/045385 A2, WO 2008/045386 A2, WO 2008/045394 A2 — all published 17 April 2008. These are a six-member Raf-kinase/inhibitor family (publication date 2008-04-17, i.e., § 102(b) art relative to the 2009-08-28 priority date). Descriptions: heteroaryl/aryl-pyrazole and related kinase-inhibitor scaffolds and pharmaceutical compositions. They do not disclose encorafenib or its 5-chloro-2-fluoro-3-(methanesulfonamido)phenyl-pyrazolyl-pyrimidine combination.
• US 2011/0196419 A1 (2011-08-11) and US 2011/0087238 A1 (2011-04-14) — cited in the family search report; post-priority.
• WO 2011/097095 A1 (2011-08-11) — post-priority (and a family-adjacent kinase application).

3. § 102 conclusion — reference by reference

No cited reference anticipates any of claims 1–16. The reasons are structural and can be stated cleanly:

1. Claim 1 is a species-plus-method claim. Anticipation under § 102 requires a single reference disclosing every element arranged as in the claim (Verdegaal Bros. v. Union Oil; In re Gleave). None of the cited documents — not Goodacre, not Trivedi, not the priority document, not WO 00/31063, WO 03/055860, WO 2005/047266, WO 2008/045361–045394, or any of the later WO/JP items — discloses the single compound encorafenib (methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate) or a salt thereof, let alone its administration to treat cancer. There is therefore no § 102 anticipation of claim 1 (and, a fortiori, none of dependent claims 2–16, which are narrower).

2. The closest art only reaches the genus, and only for claims that were never issued. References such as the WO 2008/045361-series Raf-kinase applications, WO 2009/016460, WO 2007/021966, and WO 2003/055860 are the only cited documents that come near the pyrazole/heteroaryl-kinase structural space. Even so, they disclose different Markush genera without the specific 5-chloro-2-fluoro-3-sulfonamido-phenyl / 1-isopropyl-pyrazol-4-yl / 2-aminopyrimidine / (S)-2-(methoxycarbonylamino)propyl amino combination that defines encorafenib. Their proper role is as § 103 obviousness art (and for the abandoned broad "Formula I" claims they would have been the real § 102 concerns), not § 102 against the granted claims.

3. Timing disqualifies most of the list outright. The large block of WO/JP/US publications dated 2010–2013 post-dates the 2009-08-28 priority date (and most post-date the 2010-08-27 parent filing). Under pre-AIA § 102, printed publications must predate the critical date to be § 102(b) art, and foreign-language WO/JP publications cannot serve as § 102(e)/(a)(2) "secret prior art." These items are therefore not § 102 art at all against these claims; at most they evidence the state of the art post-dating the invention.

4. WO 2011/025927 A1 is the family's own publication (Array/IRM, priority 2009-08-28, claiming the same subject matter). It is a family member, not prior art, and is expressly excluded by the § 102(b)(2) exceptions and/or the § 103(c) common-ownership provision.

5. The two verified NPL items (Goodacre 2006, Trivedi 2010) are structurally and functionally unrelated to encorafenib. They cannot anticipate under § 102(a)/102(b) for any of claims 1–16.

4. Practical bottom line

• Relevant prior art for US 10,005,761, considered strictly under § 102: effectively none. The issued claim set is a second-medical-use/species claim to encorafenib and to encorafenib + binimetinib dosing; no cited reference discloses that species.
• The most substantively meaningful cited art (i.e., the art that actually mattered during prosecution of the family) is the Raf-kinase pyrazole/heteroaryl genus art, principally the WO 2008/045361-series (pub. 2008-04-17) and the WO 2003/055860 / WO 2005/047266 / WO 2007/021966 / WO 2009/016460 group. These are § 103 references directed at the generic scaffold, not § 102 anticipatory references against the granted claims.
• Higher-value § 102/§ 103 risk to this patent family lies elsewhere than the face-of-patent citations — i.e., in inter-family double-patenting/obviousness-type double-patenting relative to the sibling patents (US 9,850,229; US 9,850,230; US 10,576,080; US 10,568,884) and in the reissue RE49,556 noted in the prior section — plus any intervening public disclosure of encorafenib between 2009 and 2016. Those should be the focus of any validity challenge or clearance analysis, not the older genus art.

Researcher's caveat

Because I could not fully render the granted patent's face-of-patent "(56) References Cited" table within this session's search budget, the patent-citation inventory in § 2b is a third-party (PubChem) mapping and several dates and titles are marked unverified. Before relying on this for a filing or opinion, the exact list should be re-pulled from the USPTO PatentCenter/Global Dossier "References Cited" tab or the granted PDF. I have deliberately not filled gaps with plausible-sounding but unverified citations or dates.

I'll verify the claim set and the key prior-art references before building the § 103 analysis, since the prior sections contain a claim-numbering conflict I need to resolve or flag.

Let me pull the actual granted claim set to resolve the claim-numbering conflict flagged in earlier sections.

Obviousness Analysis — U.S. Patent No. 10,005,761 B2 under 35 U.S.C. § 103

Scope note. Per the task instruction, this analysis is built on the references identified in the Prior-Art section of this page (the Gould/Goodacre and Trivedi NPL items, the priority document of WO 2010/100127, and the PubChem-mapped patent/WO/JP citation inventory), cross-checked against the claim scope established in the Patent-summary and Litigation sections. Where I rely on a reference's disclosure content rather than its bare citation, I say so — I could not independently render the full text of the WO 2008/045361-series or WO 2009/016460 documents in this session, and I do not fill those gaps with invented disclosures.

0. Contradiction flag (must read first)

The previously generated sections conflict on the claim set, and I am flagging it rather than silently reconciling it:

Claims 18–22 cannot exist in a 16-claim patent. Two possibilities, and they matter to the analysis:

• (a) The '761 patent issues with more than 16 claims, and the Patent-summary figure is wrong (or refers to the pre-grant publication US 2016/0263113 A1, which the summary itself notes had claims 2–18 on filing).
• (b) The litigation stipulation quoted claim numbers of the pre-reissue / sibling patents and was mis-transcribed.

Under either reading, the substantive claim scope is the same and the § 103 analysis below holds: the issued claims are method-of-use claims whose base limitation is the single species encorafenib, with dependent claims adding cancer types and combination partners (a MEK inhibitor; per the litigation record, ARRY-438162 / binimetinib). The Orange Book listings are consistent with that — 10,005,761 appears against ENCORAFENIB (BRAFTOVI, N 210496) under use codes U-2335/U-2802/U-2803 and against BINIMETINIB (MEKTOVI, N 210498) under use code U-2331, i.e. pure method-of-use codes, not DS/DP. See the OB extract at https://thefdalawblog.com/wp-content/uploads/2021/01/Orange-Book-41st-Annual.pdf and https://patents.justia.com/patent/10005761.

I also flag a second conflict: the Litigation section says the April 16, 2024 construction held the term "ARRY-438162" indefinite; the PTAB section describes the same order as construing "crystallized [binimetinib]." Both cannot be true. I do not resolve it and I do not rely on either as the sole basis for any conclusion below.

1. What § 103 must show here

Governing law: pre-AIA 35 U.S.C. § 103(a). The '761 patent (app. 15/070,905, filed 2016-03-15) is a continuation of 13/931,111 (2013-06-28), itself a divisional of 12/870,130 (2010-08-27, now US 8,501,758), claiming priority to US 61/238,073 (2009-08-28) and US 61/313,039 (2010-03-11). Because every '761 claim is supported by the 2010 disclosure (encorafenib is disclosed in the '758/'575 family — see Technical Disclosure Commons, https://www.tdcommons.org/cgi/viewcontent.cgi?article=6366&context=dpubs_series), the effective filing date is pre-2013-03-16, and AIA § 3(n)(1) does not apply. Pre-AIA § 102 and § 103 control, and the operative art cut-off is 2009-08-28.

The elements to be established. Claim 1 (per the Patent-summary section) requires three elements in combination:

1. the single species methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamido-phenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate (encorafenib, CAS 1269440-17-6, C22H27ClFN7O4S), or a pharmaceutically acceptable salt thereof;
2. administering a therapeutically effective amount; and
3. to a subject for treating cancer.

The dependency trap — the single most important point in this analysis. Every dependent claim (cancer types; combinations with a MEK inhibitor; ARRY-438162 dosing formats) incorporates element 1 by reference. A dependent claim cannot be obvious if the independent claim from which it depends is non-obvious on the art of record. Consequently:

All § 103 pressure in this patent collapses onto one question: was the encorafenib species obvious as of 2009-08-28? If not, no claim in the patent is obvious — including the much easier-to-attack combination claims. A defendant that briefs the Raf+MEK combination without first killing encorafenib has briefed the wrong case.

2. Legal framework distilled

• Graham v. John Deere Co., 383 U.S. 1 (1966) — scope/content of art, differences, PHOSITA level, secondary considerations.
• KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) — combination of known elements with known functions is obvious; "obvious to try" requires a finite number of identified, predictable solutions with a reasonable expectation of success; a patent's own disclosure cannot supply the missing "why."
• In re Baird, 16 F.3d 380 (Fed. Cir. 1994) — a broad Markush genus does not, without more, render a species obvious.
• In re Jones, 958 F.2d 347 (Fed. Cir. 1992) — same rule.
• In re Dillon, 919 F.2d 688 (Fed. Cir. 1990) (en banc) — structural similarity + shared utility establishes a prima facie case; rebuttable by unexpected properties.
• Lead-compound line: Otsuka Pharm. Co. v. Sandoz, Inc., 678 F.3d 1280 (Fed. Cir. 2012); Takeda Chem. Indus. v. Alphapharm, 492 F.3d 1350 (Fed. Cir. 2007); Eisai Co. v. Dr. Reddy's Labs., 533 F.3d 1353 (Fed. Cir. 2008); Pfizer, Inc. v. Apotex, 480 F.3d 1348 (Fed. Cir. 2007) — the challenger must show (i) the art would have selected a particular lead compound and (ii) a reason to modify it with a reasonable expectation of success.
• In re Papesch, 315 F.2d 381 (CCPA 1963) — homolog/isomer prima facie case, rebuttable by unexpected results.
• In re Petering, 301 F.2d 676 (CCPA 1962) — a small disclosed genus reciting the species can even anticipate.

The framework matters: encorafenib is a species, and every reference in this record is a genus. That asymmetry drives the outcome.

3. The art actually available, weaponized

Grouped by what each group can and cannot do:

Critical observation from the record: the Prior-Art section was unable to identify any reference disclosing encorafenib, and I could not find one either. The closest art (Group A) is genus-level. Group C is a different scaffold in a different therapeutic area. Group E is time-barred. Group F is the patentee's own work.

4. Candidate combination #1 — scaffold assembly (Group A + Group C)

The combination: WO 2008/045361-series (aryl/heteroaryl-pyrazole Raf inhibitors for cancer) + Goodacre 2006 (an amino[hetero]pyrimidine scaffold).

The articulated motivation (as a challenger would plead it):

1. Same field, same problem — both touch kinase-relevant heteroaryl scaffolds; Group A is expressly directed at Raf and proliferative disease.
2. Predictable engineering — a PHOSITA "knows" that a 2-aminopyrimidine is a classic kinase hinge-binder and that a 1H-pyrazol-4-yl is a classic kinase-scaffold linker; combining two known pharmacophores is the archetypal KSR argument.
3. Route of synthesis is known — the '761 specification itself recites the Suzuki coupling of a 3-iodo-1-isopropyl-pyrazol-4-yl pyrimidine with an aryl boronate, i.e. standard chemistry.

Why this combination fails: Goodacre is not about kinases at all — it is a GABA_A benzodiazepine-site anxiolytic paper (per the NPL description in the Prior-Art section). Using it to supply a kinase hinge-binder teaches away by irrelevance; there is no "known function" for the element being combined. Under KSR, the combination must be of elements with known functions deployed to solve the same problem. Goodacre solves anxiety, not B-Raf V600E melanoma. This is the weakest of the proposed combinations.

5. Candidate combination #2 — substituent selection / PK optimization (Group A + Group A)

The combination: A Raf-pyrazole genus (e.g., WO 2008/045361-series) as lead compound source, + a second kinase genus teaching aryl-sulfonamide groups (e.g., WO 2007/021966; WO 2009/016460; WO 2003/055860; WO 2005/047266) as the pharmacokinetic-tuning element.

The articulated motivation:

1. Sulfonamides (methanesulfonamide, propane-1-sulfonamide, cyclopropanesulfonamide) were a known means of installing a metabolically stable, weakly acidic, solubilizing group on an aniline of a kinase inhibitor — the exact motif later seen on vemurafenib (propane-1-sulfonamido-difluoroaniline) and structurally prefigured in many Group A genera.
2. Fluorine for metabolic blocking on the aniline ring was routine.
3. N-alkylation of the pyrazole (isopropyl/ethyl) and 2-(alkoxycarbonylamino)alkylamino decoration of the aminopyrimidine were each conventional from the Group A genera.
4. "Routine optimization of a known scaffold," which KSR permits where the art teaches the variables are optimization parameters.

Why this combination is strong on paper but weak in fact: This is the only combination that credibly gets all the way to a structure resembling encorafenib. But it suffers the fatal Baird defect: the Group A genera are enormous. Even taken at the level of the '761 patent's own Formula I (which is the narrowed genus actually claimed in the family), the permutations across R1 (with X1, X2, R8a, R8b), R2/R3/R5/R6 (six options each), R4 (R9 across five ring classes plus NR10R11), R7 and Y run into many millions of structures. The art therefore does not present the "finite number of identified, predictable solutions" that KSR requires; it presents a combinatorial sea. Baird and Jones are directly on point: a broad genus does not render a species obvious.

6. Candidate combination #3 — the Raf + MEK pair (the combination claims)

The combination: any Group A Raf genus + a MEK-inhibitor reference (the '761 record itself cites the ARRY-438162 ClinicalTrials.gov listing, last updated 2012 — https://pubchem.ncbi.nlm.nih.gov/patent/US-10005761-B2 — and the specification names PD-0325901, AZD6244, GSK1120212, ARRY-438162, RDEA119, GDC-0973, TAK-733, RO5126766, XL-518).

The articulated motivation — this is the strongest § 103 case in the patent, on its own terms:

1. Same pathway — Ras–Raf–MEK–ERK. Agents acting on the same linear cascade are the paradigm case for combination (and KSR's "combination of known elements according to known methods").
2. Known clinical practice — oncology multi-agent regimens were standard; the art taught combining a Raf inhibitor with a downstream MEK inhibitor to blunt resistance and to blunt the paradoxical Raf-inhibitor-driven pMEK/pERK induction that the '761 specification itself documents (FIG. 1).
3. Known, available partner — ARRY-438162 was in clinical development and publicly documented by 2009–2012.
4. Dosing formats (fixed, non-fixed, sequential) are conventional pharmaceutical-combination mechanics.

Two decisive qualifications:

• (a) The dependency trap. Because the combination claims depend from claim 1 and therefore incorporate the encorafenib limitation, they are not obvious unless encorafenib is. Under § 103, a claim incorporating a non-obvious limitation is non-obvious absent an independent ground. The Raf+MEK argument can only attack a hypothetical independent claim to "a combination of a Raf inhibitor and a MEK inhibitor" — and, if such a claim exists, it is the one the district court appears to have already disposed of on § 112 grounds (the ARRY-438162 / crystallized-binimetinib indefiniteness holding).
• (b) The patentee's own insight is not prior art. The FIG. 1 "Raf inhibitor induces ERK signaling, MEK inhibitor reverses it" data is the '761 patent's own disclosure. A § 103 case built on it is impermissibly reconstructed from the patent (KSR: "the diversity of inventive pursuits … cannot be reduced to a formula"; and the Federal Circuit's repeated prohibition on using the specification as the roadmap).

The honest assessment: for a hypothetical broad Raf+MEK combination claim, § 103 would likely succeed — KSR/routine-optimization jurisprudence strongly favors the challenger. For the issued dependent claims, it fails for the dependency reason.

7. Candidate combination #4 — the "small genus / Petering" argument (Group D)

If the priority document of WO 2010/100127 (U.S. 61/209,311) were shown to recite a small, specifically enumerated genus that includes encorafenib — or to recite the 5-chloro-2-fluoro-3-(methanesulfonamido)phenyl substituent in combination with the 1-isopropyl-pyrazol-4-yl-pyrimidin-2-amine core — the argument would shift from § 103 to § 102 anticipation under In re Petering, or the § 103 case would become materially stronger. Nothing in the Prior-Art section supports that; the section expressly states the document "does not disclose encorafenib." This is the single highest-value documentary question for any challenger and should be verified against the actual text.

8. Claim-by-claim § 103 disposition

9. The decisive rebuttal even if a prima facie case is made

Even assuming a challenger assembled Combination #2 or #3 well enough to shift the burden, the patent's own data supplies a Dillon/Papesch rebuttal of the kind the Federal Circuit credits:

• Unpredictable SAR across close analogs. The specification states a >30-fold activity difference between compound 9 (encorafenib) and compound 29 (A375 IC50 2 nM vs 76 nM) — compounds that differ essentially in the R1 group. That is the adverse side of In re Papesch: near-identical structures producing large, unpredictable property differences.
• Unpredictable PK. Human extraction ratio (ER) 0.21 for compound 9 vs 0.69 for compound 6; and an oral AUC at 10 mg/kg of 30 ± 4 µM·hr for compound 9 versus compounds 1, 3, 4, 6 and 7.
• Selectivity. The specification claims a preferred selectivity window over p38.

These are the classic "unexpected properties" that rebut a structural-similarity prima facie case — and, critically, they are measured against the closest analogs, which is where such showings carry the most weight. A challenger must be prepared to argue that these differences are merely "different," not "unexpectedly better," or that the art suggested optimizing the very parameters measured. That is a defensible position for the patentee.

10. Bottom line

1. The art of record cannot invalidate any issued claim of the '761 patent under § 103. Every cited reference is either (i) a genus that does not disclose the species (Baird, Jones), (ii) an unrelated scaffold/target (Goodacre, Trivedi), (iii) time-barred (the post-2009/2010 WO/JP/US publications), or (iv) the patentee's own non-§ 103 family disclosure (US 8,501,758; WO 2011/025927).
2. The strongest theoretical combination is a Group A Raf-pyrazole genus as lead compound + a Group A aryl-sulfonamide teaching as the PK-optimization element (Combination #2). Its fatal flaw is the sheer size of the genus and the absence of any guidance singling out the 5-chloro-2-fluoro-3-(methanesulfonamido)phenyl / 1-isopropyl-1H-pyrazol-4-yl / 2-[(2S)-(methoxycarbonylamino)propyl]aminopyrimidine assembly.
3. The Raf + MEK combination argument is powerful but structurally useless here, because every combination claim depends from the encorafenib base claim. It would only matter against a separate independent Raf+MEK claim — and the litigation record indicates those claims were resolved on § 112 indefiniteness (the "ARRY-438162"/crystallized-binimetinib construction), not § 103.
4. Where the real invalidity risk lives is not § 103 over third-party art but: (i) § 112 indefiniteness in the combination claims (already adjudicated by stipulation for certain claims); (ii) obviousness-type double patenting against the family's earlier genus/species disclosures (US 8,501,758; WO 2011/025927), which is a § 103-adjacent doctrine that the cited-art list does not address; and (iii) any intervening public disclosure of encorafenib between 2009 and 2013 that the prior sections did not surface — this, not the face-of-patent citations, is where a challenger should dig.
5. Recommended next step for a challenger: obtain the full text of WO 2008/045361 / 045367 / 045376 / 045385 / 045386 / 045394 and WO 2009/016460, and run a substructure search on the 1-isopropyl-3-aryl-1H-pyrazol-4-yl-pyrimidin-2-amine core with a sulfonamido-aniline on the C3 aryl across the pre-2009-08-28 corpus. If a single reference discloses that core with the 5-Cl/2-F/3-NHSO2Me substitution pattern (or a small enumerated genus containing it), the case converts from a losing § 103 argument into a winning § 102 argument — which is the only path that matters given the dependency structure.

11. Verification caveats

• Claim numbering is unresolved and contradictory across the prior sections (§ 0 above). The § 103 conclusions above are driven by the scope of the claims, not by their numbers, so they survive either reading — but the numbers must be confirmed against the granted PDF or the USPTO file wrapper before any of this is quoted in a brief.
• I did not verify the actual disclosure content of the WO 2008/045361-series, WO 2007/021966, WO 2009/016460, WO 2003/055860, WO 2005/047266, or the WO 2010/100127 priority document. The Prior-Art section flagged that its patent-citation inventory derives from a third-party (PubChem) mapping with unverified titles and dates. Treat every substantive statement about those documents' contents above as conditional on their actual text.
• I assume the claims are method-of-use claims consistent with the Orange Book use codes (U-2335/U-2802/U-2803 for BRAFTOVI; U-2331 for MEKTOVI). If the '761 patent in fact contains compound claims to a genus or sub-genus (the Google Patents "prior art keywords" — propan, pyrazol, chloro, pyrimidin, methyl — are consistent with either), the § 103 analysis would be materially easier for a challenger, because genus claims are not protected by the Baird species-selection doctrine. This assumption should be confirmed first.
• No statement here is a legal opinion or a freedom-to-operate/validity opinion; the primary references should be read in full before any § 103 position is taken.